The financing round will support uBiome's ongoing efforts to commercialize its clinical microbiome analysis, sexually-transmitted disease, and gut wellness tests.
The sequencing-based, laboratory-developed test, called SmartJane, contains the first commercially available vaginal microbiome assay.
The collaborators plan to collect samples that will allow them insight into participants' microbiomes in order to understand disease mechanisms over time.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.